Åland Islands

Reimbursed Care Access

Åland, as an autonomous region, administers its own health services but is subject to Finnish national drug law for controlled substances; therefore the clinical and reimbursement landscape for psychedelics mirrors Finland’s legal framework. Approved medical products (notably esketamine/Spravato under EMA authorisation) may be available in specialist settings and subject to Finland’s reimbursement/authorization pathways (Kela / Pharmaceuticals Pricing Board), while classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) remain controlled and accessible only inside authorised clinical research or not at all outside trials.